The supreme court is poised to decide whether to preserve access to a widely used abortion medication, after extending its deadline to act until at least Friday.
Less than a year after the court’s conservative majority overturned Roe v Wade and eliminated a constitutional right to an abortion, the justices are now weighing new legal questions in an escalating case in Texas with potentially sweeping implications for women’s reproductive health and the federal drug approval process.
For now, the court is not weighing the merits of a legal challenge brought by abortion opponents seeking to suspend the Food and Drug Administration’s 23-year-old approval of mifepristone. At issue before the court is whether to allow restrictions on the drug imposed by a lower court that would sharply limit access to the drug, including in states where abortion remains legal.
The justices had initially set a deadline of 11.59pm on Wednesday, but that afternoon, Justice Samuel Alito issued a brief order extending the court’s deadline by 48 hours. The one-sentence order provided no explanation for the delay but indicated the court expects to act before midnight on Friday.
The legal clash began in Texas, with US district judge Matthew Kacsmaryk’s ruling to revoke the FDA’s approval of mifepristone, a drug first approved more than two decades ago and used by more than 5 million women to end their pregnancies.
The Biden administration immediately appealed the decision, which it assailed as an unprecedented attack on the the FDA’s decision-making. The US court of appeals for the 5th circuit then temporarily blocked the Texas decision, preserving access to mifepristone while the legal case plays out, but reversed regulatory actions taken by the FDA since 2016 that expanded access to the pill. Those changes include allowing patients to receive the drug by mail, and extending its use from seven to 10 weeks of pregnancy.
The Biden administration and drugmakers next asked the supreme court to pause the lower court’s ruling, arguing that reimposing the barriers would create chaos in the marketplace and cause confusion for providers and patients.
Alliance Defending Freedom, a coalition of anti-abortion doctors and organizations, has argued that the FDA failed to follow proper protocols when it approved mifepristone and has since ignored safety risks of the medication. Medical experts have said the claims are dubious and not based on scientific evidence.
Complicating the legal landscape around this case, a federal judge in Washington state, Thomas Rice, issued a contradictory ruling in a separate lawsuit brought by Democratic attorneys general in 17 states and the District of Columbia. The order, which Rice reaffirmed after the appeals ruling in the Texas case, blocked the FDA from limiting the availability of mifepristone in those states.
Since the fall of Roe, more than a dozen US states have banned or severely restricted abortion. But many other states have moved in the opposite direction, approving legislation and ballot measures that protect abortion rights. Amid the patchwork legal landscape, attention has turned to medication abortion, which can be obtained by mail and administered at home.
Mifepristone is the first pill in a two-drug regimen that is the most common method of ending a pregnancy, accounting for more than half of all abortions in the US. Decades of research and data from hundreds of medical studies have shown that it is both a safe and effective way to end a pregnancy.
The drug first won FDA approval in 2000, and over the years the agency has loosened restrictions on its use. Those changes include allowing the drug’s use from seven to 10 weeks of pregnancy, lowering the dosage of mifepristone needed to safely end a pregnancy, allowing the pills to be delivered by mail, eliminating the in-person doctors visit requirement and approving a generic version.
Depending on how the justices rule, those changes could be reversed, at least while the case proceeds through the courts. On Wednesday, GenBioPro, the manufacturer of the generic form of mifepristone, sued the FDA to keep the drug on the market, setting up a new front in the legal battle over access to abortion medication.
Source: US Politics - theguardian.com
